Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton Sells 15,271 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton sold 15,271 shares of the business’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the completion of the sale, the chief executive officer now owns 895,941 shares in the company, valued at approximately $12,113,122.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Mineralys Therapeutics Price Performance

NASDAQ:MLYS opened at $13.94 on Thursday. The stock has a market cap of $692.11 million, a PE ratio of -6.37 and a beta of 1.93. The stock’s 50-day moving average is $12.00 and its two-hundred day moving average is $12.43. Mineralys Therapeutics, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same period in the previous year, the company earned ($0.31) earnings per share. On average, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a report on Thursday, August 15th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Mineralys Therapeutics by 0.5% in the first quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock valued at $12,690,000 after purchasing an additional 4,952 shares in the last quarter. Driehaus Capital Management LLC raised its stake in Mineralys Therapeutics by 40.4% during the second quarter. Driehaus Capital Management LLC now owns 257,371 shares of the company’s stock worth $3,011,000 after acquiring an additional 74,074 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Mineralys Therapeutics by 60.1% during the second quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company’s stock worth $6,230,000 after purchasing an additional 200,000 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Mineralys Therapeutics by 17,821.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock worth $35,000 after purchasing an additional 4,099 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Mineralys Therapeutics by 72.5% during the second quarter. Bank of New York Mellon Corp now owns 84,762 shares of the company’s stock worth $992,000 after purchasing an additional 35,634 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.